Top of the morning to you. Another harried moment here on the Pharmalot corporate campus as we hustle the short people off to the schoolhouses. We know you can relate. To cope, yes, we are brewing the mandatory cup of stimulation - our flavor today is Cinnamon Cream Swirl - as we turn our attention to the list of things to read, people to call and ideas to ponder. Feel free to send along interesting possibilities. Meanwhile, here are some tidbits. Have a great day, everyone...
Agenus Agent Is Effective In Malaria Vaccine Trial (Mass High Tech)
Glaxo May Bid For Human Genome Sciences (The Daily Mail)
FDA Warns Glaxo On Plant Violations (Dow Jones)
Surprising New Uses For Older Drugs (The Wall Street Journal)
Glaxo To Cut 60 Jobs In Quebec (Winnipeg Free Press)
UK's NICE OKs Lilly And Amylin Bydureon Diabetes Med (Bloomberg News)
FDA Panel Votes Teva Parkinson's Med Does Not Slow Disease (Dow Jones)
Express Scripts Rejects Walgreens Tricare Offer (Associated Press)
J&J Neuroscience Head Urges R&D Pooling (MarketWatch)
AstraZeneca And Forest Start Late-Stage Superbug Drug Study (Reuters)
Patient Recruitment Hurt By Mistrust Of Clinical Trials (Outsourcing Pharma)
Indian, Chinese Pharma Putting Nigerian Drugmakers Under (AllAfrica)
French Pharma Spending Projected To Decline (Pharma Times)
EDITOR'S NOTE: Please check this post for updates throughout the morning
1 Comment
Slowing of patient recruitment into US clinical trials will be temporary, IMO. The reason is that many patients participate in trials because they don't have or can't afford health insurance. Already we are seeing that, in anticipation of full implementation of Obamacare in 2014 the rolls of the uninsured have been increasing. This will have the net effect of increasing the recuitment pool of uninsured subjects over the next several years.